$NWBO -Direct is a paradigm shift because it targets the dendritic cell—the immune system's rate-limiting instructor—restoring surveillance, discrimination, and tolerance upstream. This single platform corrects corrupted programming in bone marrow and tissues, self-fixing effector failures across silos instead of lifelong symptom management.
The autologous unloaded design is safest: patient's own alpha-DC1s eliminate rejection or foreign antigen risks; in-situ capture ensures precise, self-correcting responses tailored to individual pathology, avoiding off-target toxicity, autoimmunity, or mismatched immunity seen in loaded vaccines or biologics.
Global savings: listed categories (cancer, atherosclerosis/MI/stroke, Alzheimer's, RA/MS/IBD/T1D, infections, frailty) drive ~$4-6T annual costs. One short-course platform replacing chronic pharmacotherapy could cut 60-80% via prevented progression and reduced hospitalizations/meds, yielding $2.5-4T yearly worldwide.
@RasmusTantholdt “I højere grad end tidligere”
Er du sød at forklare, hvornår Iran har bombet Israel, inden Israels offensiv startede for et par uger siden?
Det er misvisende - er det bevidst?